Fuller & Thaler Asset Management
SLXP

Fuller & Thaler Asset Management’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Fuller & Thaler Asset Management’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-600
Closed -$74K – 758
2014
Q2 		$74K Sell
600
-600
-50% -$66.3K ﹤0.01% 618
2014
Q1 		$124K Buy
+1,200
New +$123K 0.01% 565
2013
Q3 		– Sell
-103,900
Closed -$6.87M – 794
2013
Q2 		$6.87M Buy
+103,900
New +$5.94M 0.48% 85

Other funds holding SLXP

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fuller & Thaler Asset Management's SLXP Position: Q3 2014 in Review

Fuller & Thaler Asset Management sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q3 2014, closing a stake of 600 shares — an estimated $74K sold.

Fuller & Thaler Asset Management first reported a position in SLXP in Q2 2013 and held it in 3 quarters. The position peaked at $6.87M in Q2 2013. 348 funds tracked by Wall St. Rank hold SLXP as of Q3 2014.

  • Fuller & Thaler Asset Management reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q3 2014 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 600 SALIX PHARMACEUTICALS LTD DEL shares in Q3 2014, an estimated $74K.
  • Fuller & Thaler Asset Management first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 3 quarters.
  • Fuller & Thaler Asset Management's SALIX PHARMACEUTICALS LTD DEL position peaked at $6.87M in Q2 2013.
  • 348 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q3 2014.

Based on Fuller & Thaler Asset Management's 13F filing for Q3 2014, filed 14 Nov 2014.